- Home
- ACST vs UNCY Comparison
ACST vs UNCY Comparison
Compare ACST & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACST
- UNCY
- Stock Information
- Founded
- ACST 2002
- UNCY 2016
- Country
- ACST United States
- UNCY United States
- Employees
- ACST N/A
- UNCY N/A
- Industry
- ACST Pharmaceuticals and Biotechnology
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- ACST Health Care
- UNCY Health Care
- Exchange
- ACST Nasdaq
- UNCY Nasdaq
- Market Cap
- ACST 27.2M
- UNCY 31.9M
- IPO Year
- ACST N/A
- UNCY 2021
- Fundamental
- Price
- ACST $3.28
- UNCY $0.45
- Analyst Decision
- ACST Strong Buy
- UNCY Strong Buy
- Analyst Count
- ACST 2
- UNCY 4
- Target Price
- ACST $10.00
- UNCY $5.13
- AVG Volume (30 Days)
- ACST 23.2K
- UNCY 1.5M
- Earning Date
- ACST 11-11-2024
- UNCY 11-12-2024
- Dividend Yield
- ACST N/A
- UNCY N/A
- EPS Growth
- ACST N/A
- UNCY N/A
- EPS
- ACST N/A
- UNCY N/A
- Revenue
- ACST N/A
- UNCY N/A
- Revenue This Year
- ACST N/A
- UNCY N/A
- Revenue Next Year
- ACST N/A
- UNCY N/A
- P/E Ratio
- ACST N/A
- UNCY N/A
- Revenue Growth
- ACST N/A
- UNCY N/A
- 52 Week Low
- ACST $1.98
- UNCY $0.20
- 52 Week High
- ACST $3.59
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- ACST 60.89
- UNCY 66.31
- Support Level
- ACST $3.20
- UNCY $0.35
- Resistance Level
- ACST $3.44
- UNCY $0.41
- Average True Range (ATR)
- ACST 0.17
- UNCY 0.03
- MACD
- ACST 0.01
- UNCY 0.01
- Stochastic Oscillator
- ACST 70.08
- UNCY 97.37
About ACST Acasti Pharma Inc.
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.